Claims
- 1. The method of inhibiting growth of solid tumors in a mammal which comprises administering to said mammal an amount effective to inhibit growth of solid tumors of a compound capable of inhibiting growth of solid tumors, said compound selected from the group consisting of those of the formulae: ##STR11## wherein Q is a divalent moiety selected from the group consisting of those of the formulae: ##STR12## wherein n is an integer from 2 to 4, inclusive; R.sub.1 and R.sub.2 are each individually selected from the group consisting of hydrogen, alkyl having from 1 to 4 carbon atoms and monohydroxyalkyl having from 2 to 4 carbon atoms and wherein the carbon atom alpha to the nitrogen atom may not bear an hydroxy group; the leuco bases and tautomers thereof; and the pharmacologically acceptable acid-addition salts thereof; said solid tumors being those that are susceptible to growth inhibition in said mammal by administration of said compound.
- 2. The method of claim 1 wherein Q is --CH.sub.2 CH.sub.2 --.
- 3. The method of claim 2 wherein said compound is selected from the group:
- a. Leuco-1,4-bis[(2-dimethylaminoethyl)amino]-5,8-dihydroxyanthraquinone;
- b. 1,4-Bis[(2-dimethylaminoethyl)amino]-5,8-dihydroxyanthraquinone;
- c. Leuco-1,4-bis[(2-diethylaminoethyl)amino]-5,8-dihydroxyanthraquinone;
- d. 1,4-Bis[(2-diethylaminoethyl)amino]-5,8-dihydroxyanthraquinone;
- e. the dihydrochloride salt of 1,4-bis[2-(2-hydroxyethylamino)ethylamino]-5,8-dihydroxyanthraquininone; and
- f. 1,4-Bis(2-aminoethylamino)-5,8-dihydroxyanthraquinone or its dihydrochloride salt.
- 4. The method of inducing regression of leukemia cell growth in a mammal which comprises administering to said mammal an amount effective to induce regression of leukemia cell growth of a compound capable of inducing regression of leukemia cell growth, said compound selected from the group consisting of those of the formulae: ##STR13## wherein Q is a divalent moiety selected from the group consisting of those of the formulae: ##STR14## wherein n is an integer from 2 to 4, inclusive; R.sub.1 and R.sub.2 are each individually selected from the group consisting of hydrogen, alkyl having from 1 to 4 carbon atoms and monohydroxyalkyl having from 2 to 4 carbon atoms and wherein the carbon atom alpha to the nitrogen atom may not bear an hydroxy group; the leuco bases and tautomers thereof; and the pharmacologically acceptable acid-addition salts thereof.
- 5. The method of claim 4 wherein Q is --CH.sub.2 CH.sub.2 --.
- 6. The method of claim 5 wherein said compound is 1,4-bis(2-aminoethylamino)-5,8-dihydroxyanthraquinone or its dihydrochloride salt.
- 7. The method of claim 4 wherein said compound is selected from the group consisting of:
- a. Leuco-1,4-bis[(2-dimethylaminoethyl)amino]-5,8-dihydroxyanthraquinone;
- b. 1,4-Bis[(2-dimethylaminoethyl)amino]-5,8-dihydroxyanthraquinone;
- c. Leuco-1,4-bis[(2-diethylaminoethyl)amino]-5,8-dihyroxyanthraquinone;
- d. 1,4-Bis[(2-diethylaminoethyl)amino]-5,8-dihydroxyanthraquinone;
- e. the dihydrochloride salt of 1,4-Bis[2-(2-hydroxyethylamino)ethylamino]-5,8-dihydroxyanthraquinone.
- 8. The method of claim 7 wherein said compound is Leuco-1,4-bis[(2-dimethylaminoethyl)amino]-5,8-dihydroxyanthraquinone.
- 9. The method of claim 7 wherein said compound is 1,4-bis[(2-dimethylaminoethyl)amino]-5,8-dihydroxyanthraquinone.
- 10. The method of claim 7 wherein said compound is Leuco-1,4-bis[(2-diethylaminoethyl)amino]-5,8-dihyroxyanthraquinone.
- 11. The method of claim 7 wherein said compound is 1,4-bis[(2-diethylaminoethyl)amino]-5,8-dihydroxyanthraquinone.
- 12. The method of claim 7 wherein said mammal is a mouse.
CROSS REFERENCE TO RELATED APPLICATION
This application is a continuation of application Ser. No. 485,143, filed Apr. 15, 1983, which is a division of application Ser. No. 244,452, filed Nov. 2, 1981, now U.S. Pat. No. 4430501 which is a division of application Ser. No. 63,285, filed Aug. 2, 1979, now U.S. Pat. No. 4,278,689 which is a division of application Ser. No. 923,602, filed July 11, 1978, now U.S. Pat. No. 4,197,249 which is a continuation-in-part of abandoned application Ser. No. 873,040, L filed Jan. 30, 1978 which is a continuation-in-part of abandoned application Ser. No. 824,872, filed Aug. 15, 1977.
US Referenced Citations (22)
Foreign Referenced Citations (2)
| Number |
Date |
Country |
| 1157506 |
Jul 1969 |
GBX |
| 1475081 |
Jun 1977 |
GBX |
Non-Patent Literature Citations (12)
| Entry |
| Chemical Abstracts, vol. 61, No. 1977e (1964). |
| Chemical Abstracts, vol. 62, No. 11947d (1965). |
| Chemical Abstracts, vol. 80, No. 16445j (1974). |
| Chemical Abstracts, vol. 83, No. 201736g (1975). |
| Chemcial Abstracts, vol. 88, No 83369t (1978). |
| Simon, J. Am. Chem. Soc., vol. 85, p. 1974 (1963). |
| Greenhalgh et al., J. Chem. Soc., p. 1284 (1968). |
| Zee-Cheng et al, J. Med. Chem., vol. 13, p. 264 (1970). |
| Zee-Cheng et al, J. Pharmacuetical Sciences, vol. 59, p. 1630 (1970). |
| Paull et al, J. Med. Chem., vol. 19, p. 337, (1976). |
| Zee-Cheng et al, J. Med. Chem., vol. 21, p. 291, (1978). |
| Uyeki et al, J. Pharmaceutical Sciences, vol. 70, p. 1011 (1981). |
Divisions (3)
|
Number |
Date |
Country |
| Parent |
485143 |
Apr 1983 |
|
| Parent |
63285 |
Aug 1979 |
|
| Parent |
923602 |
Jul 1978 |
|
Continuation in Parts (2)
|
Number |
Date |
Country |
| Parent |
873040 |
Jan 1978 |
|
| Parent |
824822 |
Aug 1977 |
|
Patent Grant
4820738
